Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David H Vesole

Showing results (11-20 of 148) with videos related to

Pageof 15
Sort By:
Cancers|September 28, 2021
Rapid Progress in the Use of Immunomodulatory Drugs and Cereblon E3 Ligase Modulators in the Treatment of Multiple MyelomaGrzegorz Charliński, David H Vesole, Artur Jurczyszyn
Cancer Journal (Sudbury, Mass.)|September 22, 2021
From VAD to VRD: Is Transplant Still Needed in the Upfront Setting of Myeloma?Harsh Parmar, David H Vesole, Noa Biran
Clinical Lymphoma, Myeloma & Leukemia|April 8, 2010
Vorinostat plus bortezomib for the treatment of relapsed/refractory multiple myeloma: a case series illustrating utility in clinical practiceAmitabha Mazumder, David H Vesole, Sundar Jagannath
CA: a Cancer Journal for Clinicians|September 15, 2007
Multiple myeloma: charging toward a bright futureJed A Katzel, Parameswaran Hari, David H Vesole
Clinical Lymphoma, Myeloma & Leukemia|January 2, 2023
The Current State of Knowledge About Evolution of Multiple Myeloma to Plasma Cell LeukemiaArtur Jurczyszyn, Magdalena Olszewska-Szopa, David H Vesole
Oncology (Williston Park, N.Y.)|October 10, 2006
New questions about transplantation in multiple myelomaParameswaran Hari, Marcelo C Pasquini, David H Vesole
Clinical Lymphoma, Myeloma & Leukemia|May 28, 2026
Quad-Exposed/Refractory Multiple Myeloma: Patients Previously Treated With Anti-CD38, IMiDs, Proteasome Inhibitors, and BCMA-Targeted TherapiesMagdalena Olszewska-Szopa, David H Vesole, Artur Jurczyszyn
Clinical Lymphoma & Myeloma|November 21, 2007
Liver involvement in multiple myelomaMeghana S Bhandari, Amitabha Mazumder, David H Vesole
The Lancet. Haematology|December 4, 2018
The forgotten class of drugs for multiple myeloma: HDAC inhibitorsNoa Biran, David S Siegel, David H Vesole
Anti-Cancer Drugs|June 26, 2015
Safety of a second-generation tyrosine kinase inhibitor and novel targeted therapy for the treatment of a patient with chronic myeloid leukemia and multiple myelomaJed A Katzel, Annette Lee-Ma, David H Vesole
Pageof 15

Showing results (11-20 of 148) with videos related to

Sort By:
Pageof 15
Cancers|September 28, 2021
Rapid Progress in the Use of Immunomodulatory Drugs and Cereblon E3 Ligase Modulators in the Treatment of Multiple MyelomaGrzegorz Charliński, David H Vesole, Artur Jurczyszyn
Cancer Journal (Sudbury, Mass.)|September 22, 2021
From VAD to VRD: Is Transplant Still Needed in the Upfront Setting of Myeloma?Harsh Parmar, David H Vesole, Noa Biran
Clinical Lymphoma, Myeloma & Leukemia|April 8, 2010
Vorinostat plus bortezomib for the treatment of relapsed/refractory multiple myeloma: a case series illustrating utility in clinical practiceAmitabha Mazumder, David H Vesole, Sundar Jagannath
CA: a Cancer Journal for Clinicians|September 15, 2007
Multiple myeloma: charging toward a bright futureJed A Katzel, Parameswaran Hari, David H Vesole
Clinical Lymphoma, Myeloma & Leukemia|January 2, 2023
The Current State of Knowledge About Evolution of Multiple Myeloma to Plasma Cell LeukemiaArtur Jurczyszyn, Magdalena Olszewska-Szopa, David H Vesole
Oncology (Williston Park, N.Y.)|October 10, 2006
New questions about transplantation in multiple myelomaParameswaran Hari, Marcelo C Pasquini, David H Vesole
Clinical Lymphoma, Myeloma & Leukemia|May 28, 2026
Quad-Exposed/Refractory Multiple Myeloma: Patients Previously Treated With Anti-CD38, IMiDs, Proteasome Inhibitors, and BCMA-Targeted TherapiesMagdalena Olszewska-Szopa, David H Vesole, Artur Jurczyszyn
Clinical Lymphoma & Myeloma|November 21, 2007
Liver involvement in multiple myelomaMeghana S Bhandari, Amitabha Mazumder, David H Vesole
The Lancet. Haematology|December 4, 2018
The forgotten class of drugs for multiple myeloma: HDAC inhibitorsNoa Biran, David S Siegel, David H Vesole
Anti-Cancer Drugs|June 26, 2015
Safety of a second-generation tyrosine kinase inhibitor and novel targeted therapy for the treatment of a patient with chronic myeloid leukemia and multiple myelomaJed A Katzel, Annette Lee-Ma, David H Vesole
Pageof 15